BioCentury
ARTICLE | Clinical News

AJM300: Phase IIa data

May 19, 2014 7:00 AM UTC

A double-blind, Japanese Phase IIa trial in 102 patients with moderately active UC who had an inadequate response or intolerance to 5-aminosalicylic acid agents or steroids showed that thrice-daily 96...